Implementation of a Programmed Trading Mandate

Implementation of a Programmed Trading Mandate

Genticel (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, today announces that Edmond de Rothschild Investment Partners (EdRIP), a Supervisory Board member, has conferred a programmed trading mandate to an independent investment bank, Oddo Corporate Finance, for EdRIP's funds, shareholders in Genticel.

This programmed trading mandate concerns the divestment of a maximum of 865,427 shares, representing approximately 5.6% of Genticel's shares outstanding as of March 6th, 2015, over a 12-month maximum period beginning on June 4th, 2015. Thi s partial divestment is necessary because certain of EdRIP's funds will reach maturity during the mandate's period. The programmed trading mandate will be implemented in accordance with the terms and conditions, effective as of November 3rd 2010, stipulated in Recommendation n°2010-07 of the Autorité des marchés financiers (France's stock market regulators).

Financial calendar 2015

Upcoming Genticel meetings with investors

About Genticel

Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.

Genticel's most advanced candidate therapeutic vaccine, ProCervix, is currently in a Phase 2 clinical trial. ProCervix is designed to induce the elimination of cervical cells infected with HPV 16 and/or HPV 18. The company has also established Vaxiclase, a technology platform ideally adapted for use in early-intervention immunotherapies against multiple infectious or cancerous diseases. This platform is being used to develop a second therapeutic vaccine candidate, now in its preclinical stage, targeting six of the most pertinent HPV strains in terms of global epidemiology.

Genticel is based in Paris and Toulouse and was awarded 2014 “Prix Biotech d'Avenir” (Most Promising Biotech) in the SW France category of the Deloitte Technology Fast 50 Benchmark.

Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels.

For more information, please visit Genticel's website, www.genticel.com

 

© Copyright Actusnews Wire

Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com

Receive by email the next press releases of the company by registering on www.actusnews.com, it's free

Quelle: Actusnews